Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma (NCT04869137)

🧪 Interventions in This Study

• Lenvatinib Oral Product (DRUG)
• Pembrolizumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Moffitt Cancer Center — Tampa, Florida

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Merkel Cell Carcinoma

• Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma — Tampa, Florida
• Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma — Basking Ridge, New Jersey
• Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies — Phoenix, Arizona
• Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns — San Francisco, California
• ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 — Madison, Wisconsin

Explore by condition: All Merkel Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.